Hematopoietic stem cell transplantation in peripheral T-cell lymphomas

References

• The Non-Hodgkin's Lymphoma Classification Project. Clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M LA, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 76–82
   PubMed Web of Science ®Google Scholar
• Armitage J O, Greer J P, Levine A M, Weisenburger D D, Formenti S C, Bast M, et al. Peripheral T-cell lymphoma. Cancer 1989; 63: 158–163
   PubMed Web of Science ®Google Scholar
• Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon P A, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol 1990; 1: 45–50
   PubMed Web of Science ®Google Scholar
• Melnyk A, Rodriguez A, Pugh W C, Cabannillas F. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514–4520
   PubMed Web of Science ®Google Scholar
• Ansell S M, Habermann T M, Kurtin P J, Witzig T E, Chen M G, Li C Y, et al. Predictive capacity of the International Prognostic Factor index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997; 15: 2296–22301
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474–2479
   PubMed Web of Science ®Google Scholar
• Went P, Agostinelli C, Gallamini A, Piccaluga P P, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006; 24: 2472–2479
   PubMed Web of Science ®Google Scholar
• Falini B, Pileri S, Zinzani P L, Carbone A, Zagonel V, Wolf-Peeters C, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93: 2697–2706
   PubMed Web of Science ®Google Scholar
• Gascoyne R D, Aoun P, Wu D, Chhanabhai M, Skinnider B F, Greiner T C, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913–3921
   PubMed Web of Science ®Google Scholar
• Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995; 86: 1954–1960
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Munsell M, Yazji S, Hagemeister F B, Younes A, Andersson B, et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001; 19: 3766–3770
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Caballero M D, Gutierrez A, Marin J, Lahuerta J J, Sureda A, et al. High dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003; 14: 1768–1775
   PubMed Web of Science ®Google Scholar
• Song K W, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003; 120: 978–985
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz A D, Teruya-Feldstein J, Hamlin P, Yahalom J, Horwitz S, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006; 134: 202–207
   PubMed Web of Science ®Google Scholar
• Blystad A K, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001; 27: 711–716
   PubMed Web of Science ®Google Scholar
• Jantunen E, Wiklund T, Juvonen E, Putkonen M, Lehtinen T, Kuittinen O, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004; 33: 405–410
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007; 18: 652–657
   PubMed Web of Science ®Google Scholar
• Reimer P, Schertlin T, Rudiger T, Geissinger E, Roth S, Kunzmann V, et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 2004; 5: 304–311
   PubMedGoogle Scholar
• Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20: 1533–1538
   PubMed Web of Science ®Google Scholar
• Kim M K, Kim S, Lee S S, Sym S J, Lee D H, Jang S, et al. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol 2007; 86: 435–442
   PubMed Web of Science ®Google Scholar
• Nademanee A P, Zain J M, Palmer J, Tsai N, Kogut N M, Krishnan A, et al. The impact of disease status on the outcome of high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) for peripheral T-cell lymphoma (PTCL). Blood (Suppl.) 2006; 108: 871a
   Google Scholar
• D'Amore F, Relander T, Lauritzsen G, Jantunen E, Hagberg H, Anderson H, et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) as first line treatment in peripheral T-cell lymphoma (PTCL)—A phase II study of the Nordic Lymphoma Group (NLG). Blood (Suppl.) 2006; 108: 123a
   Google Scholar
• Mercadal S, Lopez-Guillermo A, Briones J, Xicoy B, Pedro C, Escoda L, et al. Is there a role for autologous stem cell transplantation (ASCT) in peripheral T-cell lymphoma (PTCL)? Final results of a prospective phase II study from the GELCAB. Blood (Suppl.) 2006; 108: 874a
   Google Scholar
• Mounier N, Gisselbrecht C, Briere J, Haioun C, Feugier P, Offner F, et al. Groupe d'Etude des Lymphomes de l'Adulte. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 2004; 15: 1790–1797
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald A P, Repp R, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103: 2920–2924
   PubMed Web of Science ®Google Scholar
• Gallamini A, Zaja F, Gargantini L, Manna A, Secondo V, Levis A, et al. CHOP-chemotherapy plus Campath-1H (CHOP-C) as first line treatment in patients with peripheral T-cell lymphoma (PTCL). Blood (Suppl.) 2005; 102: 645a
   Google Scholar
• Mollee P, Lazarus H M, Lipton J. Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma?. Bone Marrow Transplantation 2003; 31: 953–960
   PubMed Web of Science ®Google Scholar
• Dhedin N, Giraudier S, Gaulard P, Esperou H, Ifrah N, Michallet M, et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle. Br J Haematol 1999; 107: 154–161
   PubMed Web of Science ®Google Scholar
• Doocey R T, Toze C L, Connors J M, Nevill T J, Gascoyne R D, Barnett M J. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Hematol 2005; 131: 223–230
   PubMed Web of Science ®Google Scholar
• Kim S W, Tanimoto T E, Hirabayashi N, Goto S, Kami M, Yoshioka S, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 2006; 108: 382–389
   PubMed Web of Science ®Google Scholar
• Barrett A J, Savani B N. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661–1672
   PubMed Web of Science ®Google Scholar
• Faulkner R D, Craddock C, Byrne J L, Mahendra P, Haynes A P, Prentice H G, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004; 103: 428–434
   PubMed Web of Science ®Google Scholar
• Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172–2176
   PubMed Web of Science ®Google Scholar
• Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, et al. Reduced-intensity allogeneic stem cell transplantation for relapsed lymphomas: clinical and molecular outcome is different between follicular lymphoma and chronic lymphocitic leukemia. EHA Meeting 2007, Abstract 758
   Google Scholar
• Wulf G, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B. Reduced-intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin lymphoma. Bone Marrow Transplantation 2005; 36: 271–273
   PubMed Web of Science ®Google Scholar
• Okamura J, Utsunomiya A, Tanoski R, Uike N, Sonoda S, Kannagi M, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukaemia/lymphoma. Blood 2005; 105: 4143–4145
   PubMed Web of Science ®Google Scholar